Clinical trials: pMMR
Endometrial Neoplasms, Endometrial Cancer
Symbiotic-GYN-18: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Advanced or Recurrent MMR-proficient Endometrial Cancer
This study is being conducted to assess whether the study medicine PF 08634404, given in combination with chemotherapy, improves outcomes compared with another medicine called pembrolizumab plus chemotherapy.
- Trial name
- NCT07578649
- Testing
- PF-08634404, Pembrolizumab, Standard of Care Chemotherapy
- Where
- 54 sites in United States, Australia and 3 more
- Volunteers
- 600 people
- Sponsor
- Pfizer
Colon Adenocarcinoma
HDAC Inhibitor Combination With Chemoimmunotherapy in the Neoadjuvant Treatment of pMMR Locally Advanced Colon Cancer
The purpose of this clinical trial is to learn the safety and efficacy of HDAC inhibitors in combination with neoadjuvant immunochemotherapy compared to neoadjuvant therapy in the treatment of locally advanced colon cancer.
- Trial name
- NCT06709885
- Testing
- Chidamide + Tislelizumab + chemotherapy (CapeOX ), CapeOX
- Where
- China
- Volunteers
- 100 people
- Sponsor
- Daping Hospital and the Research Institute of Surgery of the Third Military Medical University
Locally Advanced Rectal Cancer (LARC)
A Pospective, Single-arm, Multicenter Clinical Trial Evaluating Preoperative Neoadjuvant mFOLFOX6 Chemotherapy in Combination With PD1 Monoclonal Antibody in MSS/pMMR Locally Advanced Rectal Cancer
Preoperative neoadjuvant chemoradiotherapy can induce tumor regression and reduce the risk of postoperative recurrence, serving as the standard treatment for locally advanced rectal cancer.
- Trial name
- FIRM (NCT06688786)
- Testing
- neoadjuvant mFOLFOX6 chemotherapy combined with PD-1 inhibitor therapy
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Xinhua Hospital, Shanghai Jiao Tong University School of Medicine
Metastatic Colorectal Cancer
Electroporation and Immunotherapy in Metastatic Colorectal Cancer
The trial is designed as an investigator initiated prospective phase 2 study in patients with metastatic pMMR colorectal cancer (CRC) to determine the safety and efficacy of calcium electroporation (CaEP) performed concurrently…
- Trial name
- ELI (NCT05609656)
- Testing
- Irreversible electroporation, Calcium electroporation, Pembrolizumab
- Where
- Denmark
- Volunteers
- 4 people
- Sponsor
- Ismail Gögenur
Colorectal Cancer
Evaluation of Efficacy and Safety of PD-1 Monoclonal Antibody in Combination With rhG-CSF, IL-2, and CapeOX in Initially Resectable Synchronous Colorectal Liver Metastases
This study attempts to employ a combination therapy using rhG-CSF, IL-2, and PD-1 inhibitors, aiming to overcome the limitations of monotherapy in immunotherapy through multi-faceted immune regulation.
- Trial name
- NCT06504901
- Testing
- Tislelizumab, Interleukin-2, Capecitabine
- Volunteers
- 30 people
- Sponsor
- The First Affiliated Hospital with Nanjing Medical University
Colorectal Cancer (Locally Advanced or Metastatic), Colorectal Cancer Microsatellite Stable (MSS)
FOLFOX Chemotherapy Combined With Fruquintinib and Serplulimab as First-Line Conversion Therapy for Initially Unresectable pMMR/MSS Colorectal Cancer
To evaluate the efficacy and safety of immune checkpoint inhibitor-based combination therapy with targeted therapy and chemotherapy in patients with locally advanced unresectable or metastatic colorectal cancer.
- Trial name
- NCT07446465
- Testing
- Serplulimab, Fruquintinib, mFOLFOX6 (oxaliplatin, calcium folinate, and 5-FU)
- Where
- China
- Volunteers
- 42 people
- Sponsor
- Ye Xu
MSS/pMMR Type Metastatic Colorectal Adenocarcinoma Patients
A Prospective, Single Arm, Open Label, Phase II Clinical Study on the Efficacy and Safety of Ivonescimab (AK112) Combined With TAS-102 in the Treatment of Refractory MSS/pMMR Advanced Colorectal Cancer
A Prospective, Single Arm, Open Label, Phase II Clinical Study on the Efficacy and Safety of Ivonescimab (AK112) Combined With TAS-102 in the Treatment of Refractory MSS/pMMR Advanced Colorectal Cancer Main purpose: Evaluate the…
- Trial name
- NCT06936488
- Testing
- Ivonescimab,TAS-102
- Where
- China
- Volunteers
- 35 people
- Sponsor
- Huai'an First People's Hospital
Locally Advanced Rectal Cancer (LARC)
To Explore a Single-arm Phase II Study on Intestinal Microbiota Transplantation Combined With Neoadjuvant Immunotherapy and Chemoradiotherapy for Locally Advanced Rectal Cancer Under MSS/pMMR
To evaluate the pathological complete response rate (pCR) of intestinal flora transplantation combined with short-course radiotherapy +CAPOX+ sintilimab in neoadjuvant therapy for locally advanced rectal cancer (pMMR/MSS type)
- Trial name
- NCT07738042
- Testing
- Sintilimab, CAPOX (oxaliplatin/capecitabine), Short-course radiotherapy
- Where
- China
- Volunteers
- 46 people
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
Metastatic Colorectal Neoplasms, Microsatellite Stable / Proficient Mismatch Repair Colorectal Cancer
A Multicenter, Phase Ib/II Clinical Trial to Evaluate the Efficacy and Safety of Concurrent Combination Therapy of S-531011 Plus Fruquintinib or S-531011 Plus Fruquintinib Plus Pembrolizumab in Patients With MSS/pMMR Colorectal Cancer
This study aims to evaluate the efficacy and safety of the concurrent combination therapy of S 531011 + fruquintinib or S 531011 + fruquintinib + pembrolizumab in patients with MSS/pMMR colorectal cancer.
- Trial name
- IGNITE-CRC (NCT07591597)
- Testing
- S-531011, Fruquintinib, Pembrolizumab
- Volunteers
- 68 people
- Sponsor
- National Cancer Center Hospital East
pMMR/MSS Locally Advanced Rectal Cancer
Short-course Radiotherapy Followed by Sequential Chemotherapy With or Without PD-1 Monoclonal Antibody and Bevacizumab as Total Neoadjuvant Therapy in pMMR/MSS Locally Advanced Rectal Cancer （SPARK）
Safety and efficacy of Short-Course Radiotherapy Followed by Sequential Chemotherapy with or without PD-1 Monoclonal Antibody and Bevacizumab as Total Neoadjuvant Therapy in pMMR/MSS Locally Advanced Rectal Cancer.
- Trial name
- NCT07005570
- Testing
- Short-course radiotherapy followed by sequential chemotherapy combined with PD-1 monoclonal antibody and bevacizumab, Short-course radiotherapy followed by sequential chemotherapy
- Where
- China
- Volunteers
- 86 people
- Sponsor
- Dechang Diao
Rectal Adenocarcinoma, High-risk Locally Advanced
A Multicenter, Randomized Controlled Phase II Study of Short-Course Radiotherapy Followed by Sequential PD-1 Inhibitor and FOLFOX Chemotherapy Versus Long-Course Chemoradiotherapy for High-Risk Locally Advanced pMMR/MSS Lower Rectal Adenocarcinoma (STAR Trial)
This study adopts a prospective randomized controlled design to evaluate the efficacy and safety of short-course radiotherapy followed by sequential PD-1 inhibitor and FOLFOX chemotherapy versus conventional regimens in high-risk…
- Conditions
- Rectal Adenocarcinoma, High-risk Locally Advanced, Short-course Radiotherapy (SCRT), Immunotherapy
- Trial name
- STAR (NCT07669220)
- Testing
- Short-course Radiotherapy, SCRT, Toripalimab
- Where
- China
- Volunteers
- 76 people
- Sponsor
- Sixth Affiliated Hospital, Sun Yat-sen University
Colorectal Cancer
GSL Synthetase Inhibitor Plus Immune Checkpoint Inhibitor and/or Regorafenib in Previously Treated pMMR/MSS CRC.
In this single-center,open-label, randomized, phase II study, the efficacy and feasibility of GSL synthetase inhibitor in combination with immune checkpoint inhibitor and/or regorafenib therapeutic regimen will be evaluated in…
- Trial name
- NCT06558773
- Testing
- Regorafenib+Immune checkpoint inhibitor, Eliglustat+Immune checkpoint inhibitor, Eliglustat+Immune checkpoint inhibitor +Regorafenib
- Where
- China
- Volunteers
- 120 people
- Sponsor
- Chinese PLA General Hospital
Recurrent Endometrial Carcinoma, Unresectable Endometrial Carcinoma
Phase 1 Clinical Trial of Lenvatinib, Pembrolizumab and Hypofractionated Pelvic Radiation Therapy for pMMR Recurrent/Unresectable Endometrial Carcinoma
The purpose of this research study is to see if it is feasible to combine a fixed dose of pembrolizumab and a daily dose of oral lenvatinib, along with daily treatments of an abbreviated course of pelvic external beam radiation…
- Trial name
- NCT05603910
- Testing
- Lenvatinib, Pembrolizumab, Hypofractionated External Beam Radiation Therapy
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- Aaron Wolfson
Colorectal Cancer Metastatic
BAL/BOT/agenT-797 in pMMR CRC With Liver Metastases
The goal of this clinical trial is to learn whether the combination of balstilimab, botensilimab, and agenT-797 is safe and effective in treating adults with previously treated metastatic colorectal cancer that is microsatellite…
- Trial name
- NCT07550088
- Testing
- Balstilimab (BAL), Botensilimab (BOT), agenT-797
- Where
- United States
- Volunteers
- 17 people
- Sponsor
- Darren Sigal, MD
Colorectal Cancer
Comparing Efficacy and Safety of Enlituo® Versus Erbitux® Plus FOLFOX in Locally Advanced/Metastatic Colorectal Cancer With RAS/BRAF Wild-type and MSS/pMMR Status.
This is a randomized, double-blind, phase III clinical trial. The study aims to demonstrate that the treatment regimen of Enlituo® plus FOLFOX is equivalent to that of Erbitux® plus FOLFOX in participants with RAS/BRAF wild-type…
- Trial name
- NCT07595276
- Testing
- Enlituo®, Erbitux®
- Where
- China
- Volunteers
- 608 people
- Sponsor
- Taizhou Mabtech Pharmaceutical Co.,Ltd
Colorectal Cancer with Hepatic Metastases
TATE and KN046 in MCRC
A single-arm, multicenter, Phase IIA study of Intra-arterial Administration of Tirapazamine followed by Transarterial Embolization (TATE) and KN046 (recombinant humanized anti-PD-L1/CTLA-4 bispecific single-domain antibody Fc…
- Trial name
- NCT06834399
- Testing
- KN046 （PD-L1/CTLA4 BsAb）, TATE：Intra-arterial Administration of Tirapazamine followed by Transarterial Embolization
- Where
- China
- Volunteers
- 42 people
- Sponsor
- Zhejiang Raygene Pharmaceuticals Co., Ltd
Colon Cancer, MSS/pMMR
QL1706 Plus XELOX as Neoadjuvant Therapy for MSS/pMMR Clinical Stage III Colon Cancer
This is a single-arm, exploratory study enrolling participants with resectable stage III pMMR/MSS colon cancer. Eligible participants who provide written informed consent will receive four cycles of neoadjuvant treatment with…
- Conditions
- Colon Cancer, MSS/pMMR, QL1706
- Trial name
- NCT07156682
- Testing
- QL1706, XELOX
- Where
- China
- Volunteers
- 21 people
- Sponsor
- Qilu Hospital of Shandong University
Colorectal Cancer
PCSK9 Inhibitors in Combination With Advanced Treatment Strategies for the Treatment of Advanced Colorectal Cancer With pMMR/MSS
The purpose of this study is to preliminarily observe the efficacy and safety of PCSK9 inhibitors in combination with standard advanced first-line regimens in the treatment of advanced colorectal cancer with pMMR/MSS.
- Trial name
- NCT06391905
- Testing
- PCSK9 inhibitor in combination with standard advanced first-line regimen group, standard advanced first-line regimen group
- Volunteers
- 60 people
- Sponsor
- Guangdong Provincial People's Hospital
Rectal Cancers
Neoadjuvant Radiotherapy Combined With NALIRIFOX and Adebrelimab in pMMR/MSS Locally Advanced Rectal Cancer: A Prospective, Randomized, Phase II Clinical Trial
To explore the efficacy and safety of radiotherapy combined with Adebrelimab and NALIRIFOX in patients with pMMR/MSS locally advanced rectal cancer
- Trial name
- NCT07622771
- Testing
- Adalimumab+NALIRIFOX→Short course radiotherapy →Adalimumab+NALIRIFOX, Adalimumab+NALIRIFOX→Long course chemoradiotherapy →Adalimumab+NALIRIFOX
- Where
- China
- Volunteers
- 84 people
- Sponsor
- Sun Yat-sen University
Rectal Cancer Patients
Oncolytic Virotherapy to Enhance PReoperative IMmunotherapy Efficacy in Patients With Proficient Mismatch Repair (pMMR) Rectal Cancer
A Phase I clinical trial that will investigate the safety and tolerability of combining the modified vaccinia virus BT-001 with systemic pembrolizumab in patients with localised pMMR rectal cancer
- Trial name
- OV-PRIME-R (NCT07687875)
- Testing
- BT-001 followed by Pembrolizumab (PD-1 Blocking Antibody)
- Where
- Denmark
- Volunteers
- 20 people
- Sponsor
- Henry Smith